☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
relapsing-remitting multiple sclerosis
Sanofi's Aubagio (teriflunomide) Receives EC's Approval as First Oral MS Therapy for 1L Treatment with Relapsing-Remitting Multipl...
June 21, 2021
Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis
April 8, 2021
Biogen's Plegridy (peginterferon beta-1a- IM) Receives EC's Approval for Relapsing-Remitting MS
December 22, 2020
Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relaps...
September 3, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.